Germany-based Schering AG, majority-owned by the Bayer Group, and Stanford University have started a joint research program to develop novel molecular imaging agents for the diagnosis and follow-up of cancer. Specifically, the cooperation will focus on the identification of novel positron emission tomography (PET) tracers for tumor imaging.

Under the terms of the agreement, Schering will have the option to assume exclusive rights for the development and commercialization of such tracers.

“This research cooperation will further strengthen our commitment to the exciting and fast growing field of molecular imaging and we are proud to collaborate with Stanford University, one of the leading institutions in this field,” said Dr. Hans Maier, Head of Schering AG’s Global Business Unit Diagnostic Imaging. “With our strong network of academic and industrial partners worldwide, we aim to provide innovative options for the early and accurate detection and follow-up of cancer diseases — for the benefit of the patient.”

Posted on January 8, 2007 02:03 PM